Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030 - Poll - MDSpire

Strategies for Late-Phase Development to Address the Challenges of PD-1/PD-L1 Therapy: A Pathway Toward 2030

  • By

  • Elena A. Andresyuk

  • Natalya O. Porozova

  • Georgii D. Londaridze

  • Ivan S. Moiseev

  • Polina V. Kotselyabina

  • Yuri B. Porozov

  • July 20, 2026

Share

Original Source(s)

Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030

  • by Elena A. Andresyuk, Natalya O. Porozova, Georgii D. Londaridze, Ivan S. Moiseev, Polina V. Kotselyabina, Yuri B. Porozov

  • July 20, 2026

Related Content

Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade

Hepatic origin of increased serum TFF3 in gastric cancer bearing subjects

Inflammatory myofibroblastic tumour: unravelling the interplay of inflammation, kinase signalling, and therapeutic resistance